Trial Profile
Vaccination of patients with stage IV melanoma with dendritic cells generated ex vivo from monocytes and loaded with heat treated killed allogeneic melanoma cells.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Jun 2017
Price :
$35
*
At a glance
- Drugs ODC 0501 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Baylor Research Institute
- 02 Dec 2005 New trial record.